CardiALLO cell therapy(BioCardia)

N/A

Report date: 2023/12/20 15:34:09

Base Information

Drug NameCardiALLO cell therapy(BioCardia)

Drug Alias NameHuman Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells(BioCardia)Neurokinin 1 receptor positive mesenchymal stem cell therapy(BioCardia)NK1R+ MSC(BioCardia)NK1R+ Allogeneic BCDA-03(BioCardia)CardiALLO +[6]

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapyCell and gene therapy > Cell therapy > Source of cells > Bone Marrow-derived

Mechanisms of ActionStem cell replacementsNeurokinin 1 receptor modulators

TargetsNeurokinin 1 receptor

Therapy Area/IndicationsHeart Failure, SystolicHeart Failure

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesBiocardia Inc

China Registration ClassN/A

Develop Information

Active CompaniesBiocardia Inc

Inactive CompaniesN/A

Active IndicationsHeart Failure, SystolicHeart Failure

Inactive IndicationsN/A

Other Information

ATC CodeN/A